World Health Organization Announces Two New Candidate Vaccines To Join Ebola Trial; Two Vaccine Candidates Are Chadox1, Developed By The University Of Oxford With The Serum Institute Of India, And Moderna’s MRNA-1469; Recommended Adding Two New Ebola Vaccine Candidates To Ongoing Tumaini Clinical Trial In Democratic Republic Of Congo; Initial Findings From Treatment Trials Are Expected In Coming Months, With Results From Vaccine Trial Expected In Early 2027
https://www.who.int/philippines/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances
Share
Why It Matters
Moderna's vaccine candidate is being tested in an Ebola trial in Congo. This shows the company is working on serious health problems, though results won't come until 2027.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.